Xperi (NASDAQ:XPER) reported quarterly sales of $234.00 million which beat the analyst consensus estimate of $223.76 million by 4.58 percent. This is a 5.28 percent increase over sales of $222.27 million the same period last year.
United Nations’ Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.
